452
Participants
Start Date
December 31, 2005
Primary Completion Date
December 31, 2010
Study Completion Date
December 31, 2016
Lamivudine
4 mg/kg twice daily
Lopinavir/ritonavir
16/4 mg/kg twice daily for participants 2 months of age to less than 6 months of age; 12/3 mg/kg twice daily for participants at least 6 months of age and weighing less than 15 kg; 10/2.5 mg/kg twice daily for participants at least 6 months of age and weighing between 15 kg and 40kg; 400/100 mg twice daily for participants weighing more than 40 kg
Nevirapine
Initially: 4 mg/kg for 14 days, then 7 mg/kg twice daily. In protocol version 2.0, Letter of Amendment 1 (September 2007), NVP dose increased to conform with WHO guidelines to: 160 to 200 mg/m\^2/dose to max 200 mg once daily for 14 days, then 160 to 200 mg/m\^2/dose to max 200 mg twice daily
Zidovudine
180 mg/m\^2 twice daily
Harriet Shezi Clinic at Chris Hani Baragwanath Hospital, Johannesburg
University of Stellenbosch-Tygerberg Hospital, South Africa, Cape Town
Nelson R. Mandela School of Medicine, University of Kwazulu, Natal
BJ Medical College CRS, Pune
University of North Carolina Lilongwe CRS, Mzimba Road
Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Johannesburg
Kilimanjaro Christian Medical CRS, IDC Research Offices
Makerere University, Kampala
George Clinic CRS, Lusaka
UZ-College of Health Sciences, Harare
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
NETWORK